Integromics S.L. provides state-of-the-art bioinformatics software solutions for data management and data analysis in genomics and proteomics. Our advanced software technology, supported by an experienced and knowledgeable team of life science professionals, enhances your ability to effectively organize your data, perform validated analyses, discover new biomedical knowledge and gain well-founded insights into various areas of research.
SINCE 2014 INTEGROMICS IS A 100% PERKINELMER COMPANY
Integromics ®, Spanish company with significant international presence in the market of bioinformatics software has sold 100% of its shares to the U.S. multinational PerkinElmer (NASDAQ: PKI), global leader focused on improving the health and safety of people and the environment.
“This sale underscores the success of our country to develop from scratch a leader in a segment of highly specialized software and high international growth,” says Dr. Victor Canivell CEO Integromics. “The foundation is the development of an excellent and well-integrated multidisciplinary with professionals from the scientific and computer engineering areas as well as the ability to anticipate the needs of massive data analysis for researchers and clinicians working in genomics and personalized medicine. ”
Integromics, SL and PerkinElmer Inc began their collaboration in 2013 after signing a strategic agreement for worldwide distribution of Integromics’ OmicsOffice software. This collaboration has also led to the development of new joint solutions for bioinformatics analysis in the field of drug discovery, announced recently at the European Conference 2014 ELA held this year in Barcelona last May.
“A new horizon of development where we can leverage the potential that provides us to have the support of a multinational company that has decided to strengthen its commitment to the bioinformatics software as a differentiator of your offer is now open to our team,” says the Dr. Canivell. “Offering solutions for data analysis is becoming a priority for leading instrumentation companies, whose market kits and services are organizations working in drug discovery and therapeutic targets. “In addition, the type of solutions that Integromics develops is essential to enter in the new markets of translational and personalized medicine,” Victor concludes Canivell.